Study on the Effect of Aprepitan on Chemotherapy-related Adverse Reactions of Gynecological Malignancies

Objective: To explore the clinical efficacy and safety of aprepitan in preventing chemotherapy-associated nausea and vomiting (CINV) in patients with gynecological malignancies. Methods: A total of 98 patients with gynecological malignant tumors in our hospital from January 2020 to December 2022 were selected and randomly divided into an observation group and a control group, with 49 cases in each group. The control rates of nausea and vomiting, symptom scores and adverse reactions were compared between the two groups. Results: The total score of R-INVR in the observation group was lower than that in the control group, the remission rate of nausea and vomiting and the total score of FLIE were higher than those in the control group (p < 0.001), and the incidences of adverse reactions such as fatigue, constipation, headache, diarrhea and anorexia were all lower than those in the control group (p < 0.05). Conclusion: Aprepitan can relieve nausea and vomiting caused by chemotherapy in patients with gynecological malignant tumors, and it has good safety. It is suitable for antiemetic management during chemotherapy in gynecological malignant tumors.